Possible Biomarkers for Progression Independent of Relapse Activity Identified in RMS
Identification of candidate biomarkers associated with MS progression may enable earlier detection and individualized monitoring of Progression Independent of Relapse Activity (PIRA). According to Andrea Landwehr, who presented the results at the ECTRIMS 2025 Congress, these findings pave the way for novel therapeutic strategies that could significantly improve long-term outcomes and quality of life for people living with MS.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
